Pfizer tests Long-Term safety of promising sickle cell treatment
NCT ID NCT05632354
Summary
This study aimed to check the long-term safety of the experimental drug GBT021601 for people with sickle cell disease. It enrolled 47 participants who had already taken the drug in earlier trials, allowing them to continue treatment while researchers monitored for side effects over time. The study also looked at whether the drug continued to help control the disease by measuring blood markers and tracking painful episodes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aminu kano Teaching Hospital
Kano, 700233, Nigeria
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Lagos University Teaching Hospital
Lagos, 100254, Nigeria
-
Mississippi Center for Advanced Medicine
Madison, Mississippi, 39110, United States
-
Our Lady of the Lake Hospital, Inc.
Baton Rouge, Louisiana, 70808, United States
-
University College Hospital Ibadan
Ibadan, Oyo/ibadan North, 200212, Nigeria
-
University Medical Center Inpatient Pharmacy
New Orleans, Louisiana, 70112, United States
-
University Medical Center New Orleans
New Orleans, Louisiana, 70112, United States
-
University of Texas Health Science Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.